Compare American Electric Power Company Inc (AEP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Electric Power Company Inc vs State Street SPDR S&P Biotech ETF — how do they compare? American Electric Power Company Inc trades at $123.79 (market cap $67.28B), while State Street SPDR S&P Biotech ETF trades at $159.42. The key difference: American Electric Power Company Inc pays a 3.07% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, American Electric Power Company Inc nearer its low. Which is the better fit depends on your goals.
| AEP | XBI | |
|---|---|---|
Market Cap | $67.28B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $138.69 | $164.28 |
52-Week Low | $106.44 | $86.92 |
Enterprise Value | $120.17B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEP trades at $122.84, down 2.3% on the day, with a bearish technical signal. Recent Q2 2026 earnings missed estimates at $1.36 per share versus $1.48 expected, though revenue grew 7% year-over-year. The company raised full-year 2026 operating EPS guidance to $6.25–$6.55, supported by 69 GW of contracted load and a $78 billion capital plan. Analyst consensus remains strongly bullish with a $140.89 price target and no sell ratings.
The outlook is positive due to robust demand from data centers and infrastructure growth, but risks include high capital expenditures and interest expenses. Valuation metrics like a P/E of 21.42 are elevated, requiring sustained earnings growth to justify. The stock offers a stable dividend, with the next payment of $0.95 ex-dividend on August 10, 2026.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
